NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.39 +0.34 (+5.62 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$6.39
Today's Range$6.04 - $6.42
52-Week Range$3.39 - $15.20
Volume82,947 shs
Average Volume141,394 shs
Market Capitalization$158.70 million
P/E Ratio-2.20
Dividend YieldN/A
Beta2.38
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.11 million
Book Value$4.28 per share

Profitability

Net Income$-60,800,000.00
Net Margins-3,185.75%

Miscellaneous

Employees44
Market Cap$158.70 million
OptionableOptionable

Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) released its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.13. The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 3,185.75% and a negative return on equity of 91.11%. View Syndax Pharmaceuticals' Earnings History.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for Syndax Pharmaceuticals.

What price target have analysts set for SNDX?

6 Wall Street analysts have issued 1-year target prices for Syndax Pharmaceuticals' shares. Their predictions range from $6.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $18.60 in the next year. This suggests a possible upside of 191.1% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.

What is the consensus analysts' recommendation for Syndax Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.

Has Syndax Pharmaceuticals been receiving favorable news coverage?

Media stories about SNDX stock have been trending neutral on Saturday, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of Syndax Pharmaceuticals' key competitors?

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the folowing people:
  • Dr. Briggs W. Morrison, CEO & Director (Age 59)
  • Mr. Michael A. Metzger, Pres & COO (Age 48)
  • Mr. Richard P. Shea, CFO & Treasurer (Age 67)
  • Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)
  • Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50)

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.34%), 683 Capital Management LLC (5.41%), Dimensional Fund Advisors LP (3.26%), Bank of America Corp DE (0.92%), Orbimed Advisors LLC (0.85%) and Geode Capital Management LLC (0.73%). View Institutional Ownership Trends for Syndax Pharmaceuticals.

Which institutional investors are selling Syndax Pharmaceuticals stock?

SNDX stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, BlackRock Inc., Two Sigma Investments LP, Barclays PLC and United Services Automobile Association. View Insider Buying and Selling for Syndax Pharmaceuticals.

Which institutional investors are buying Syndax Pharmaceuticals stock?

SNDX stock was bought by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Bank of America Corp DE, MCF Advisors LLC, Caption Management LLC, Telemetry Investments L.L.C., Raymond James & Associates, Bank of New York Mellon Corp and Dimensional Fund Advisors LP. View Insider Buying and Selling for Syndax Pharmaceuticals.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $6.39.

How big of a company is Syndax Pharmaceuticals?

Syndax Pharmaceuticals has a market capitalization of $158.70 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is http://www.syndax.com.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel